From a health-care system perspective, it may be more efficient to use the drug cetuximab only in colorectal cancer patients whose tumors have a wild-type KRAS gene, according to a study published online August 7 in the Journal of the National Cancer Institute.
Full article >>
Saturday, August 8, 2009
Cost-effectiveness of cetuximab in metastatic colorectal cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment